ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,222.68
      0.16%
      US Tech 100
      17,650.00
      0.05%
      Dow Jones
      39,512.84
      0.32%
      Brent Oil
      82.585
      0.00%
      Bitcoin
      61,615.50
      1.34%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU
      6. Pharming Group NV (PHARM)

      7. Pharming Group NV (PHARM) News

      PHARM

      Pharming Group NV (PHARM)

      Pharming Group NV
      		Date:
      Sort by:
       Showing the most relevant articles for your search:EU:PHARM
      DateTimeSourceHeadlineSymbolCompany
      05/08/20241:00AMGlobeNewswire Inc.Pharming Group reports first quarter 2024 financial results and provides business updateEU:PHARMPharming Group NV
      05/08/20241:00AMGlobeNewswire Inc.Pharming Group reports first quarter 2024 financial results and provides business updateEU:PHARMPharming Group NV
      04/24/20242:00AMGlobeNewswire Inc.Pharming Group to report first quarter 2024 financial results on May 8EU:PHARMPharming Group NV
      04/24/20241:00AMGlobeNewswire Inc.Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact AwardsEU:PHARMPharming Group NV
      04/24/20241:00AMGlobeNewswire Inc.Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact AwardsEU:PHARMPharming Group NV
      04/19/202412:43PMGlobeNewswire Inc.Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
      04/18/20249:04AMGlobeNewswire Inc.Pharming Group announces the placement of €100 million convertible bonds due 2029EU:PHARMPharming Group NV
      04/18/20242:00AMGlobeNewswire Inc.Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
      04/08/20241:00AMGlobeNewswire Inc.Pharming announces completion of enrollment in pediatric clinical trial of leniolisibEU:PHARMPharming Group NV
      04/08/20241:00AMGlobeNewswire Inc.Pharming announces completion of enrollment in pediatric clinical trial of leniolisibEU:PHARMPharming Group NV
      04/04/20242:30AMGlobeNewswire Inc.Pharming Group announces the 2024 Annual General Meeting of ShareholdersEU:PHARMPharming Group NV
      04/04/20241:00AMGlobeNewswire Inc.Pharming Group announces the filing of its 2023 Annual Report and Form 20-FEU:PHARMPharming Group NV
      04/03/20242:00AMGlobeNewswire Inc.Pharming Group to participate in April investor conferencesEU:PHARMPharming Group NV
      04/03/20242:00AMGlobeNewswire Inc.Pharming Group to participate in April investor conferencesEU:PHARMPharming Group NV
      03/14/20242:00AMGlobeNewswire Inc.Pharming Group reports fourth quarter and full year 2023 financial resultsEU:PHARMPharming Group NV
      02/29/20242:00AMGlobeNewswire Inc.Pharming Group to report fourth quarter and full year 2023 financial results on March 14EU:PHARMPharming Group NV
      02/29/20242:00AMGlobeNewswire Inc.Pharming Group to report fourth quarter and full year 2023 financial results on March 14EU:PHARMPharming Group NV
      02/08/20242:00AMGlobeNewswire Inc.Pharming Group to participate in February investor conferencesEU:PHARMPharming Group NV
      02/08/20242:00AMGlobeNewswire Inc.Pharming Group to participate in February investor conferencesEU:PHARMPharming Group NV
      01/08/20241:00AMGlobeNewswire Inc.Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch updateEU:PHARMPharming Group NV
      01/08/20241:00AMGlobeNewswire Inc.Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch updateEU:PHARMPharming Group NV
      12/13/20231:00AMGlobeNewswire Inc.Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)EU:PHARMPharming Group NV
      11/21/20231:00AMGlobeNewswire Inc.Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisibEU:PHARMPharming Group NV
      11/21/20231:00AMGlobeNewswire Inc.Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisibEU:PHARMPharming Group NV
      11/10/20238:51AMGlobeNewswire Inc.Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approvalEU:PHARMPharming Group NV
      11/01/20233:00AMGlobeNewswire Inc.Pharming Group to participate in November investor conferencesEU:PHARMPharming Group NV
      11/01/20233:00AMGlobeNewswire Inc.Pharming Group to participate in November investor conferencesEU:PHARMPharming Group NV
      10/26/20231:00AMGlobeNewswire Inc.Pharming Group reports third quarter 2023 financial resultsEU:PHARMPharming Group NV
      10/12/20232:00AMGlobeNewswire Inc.Pharming Group to report third quarter 2023 financial results on October 26EU:PHARMPharming Group NV
      10/12/20232:00AMGlobeNewswire Inc.Pharming Group to report third quarter 2023 financial results on October 26EU:PHARMPharming Group NV
       Showing the most relevant articles for your search:EU:PHARM